Paul Schimmel Biography and Net Worth

Director of aTyr Pharma

Paul Schimmel, Ph.D. has served as a director since September 2005. Dr. Schimmel is currently a director of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, as well as a director of several private companies. Dr. Schimmel is an Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. Dr. Schimmel holds a B.A. in biochemistry and biophysics from Ohio Wesleyan University and a Ph.D. from the Massachusetts Institute of Technology.

What is Paul Schimmel's net worth?: The estimated net worth of Paul Schimmel is at least $0.00 as of July 22nd, 2024. Dr. Schimmel owns 354,075 shares of aTyr Pharma stock worth more than $0 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Schimmel may own. Learn More about Paul Schimmel's net worth.
How do I contact Paul Schimmel?: The corporate mailing address for Dr. Schimmel and other aTyr Pharma executives is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on Paul Schimmel's contact information.
Has Paul Schimmel been buying or selling shares of aTyr Pharma?: Paul Schimmel has not been actively trading shares of aTyr Pharma during the past quarter. Most recently, on Wednesday, May 10th, Paul Schimmel bought 200,000 shares of aTyr Pharma stock. The stock was acquired at an average cost of $2.25 per share, with a total value of $450,000.00. Following the completion of the transaction, the director now directly owns 313,023 shares of the company's stock, valued at $704,301.75. Learn More on Paul Schimmel's trading history.
Who are aTyr Pharma's active insiders?: aTyr Pharma's insider roster includes Jill Broadfoot (CFO), John Clarke (Director), Paul Schimmel (Director), and Sanjay Shukla (CEO). Learn More on aTyr Pharma's active insiders.
Are insiders buying or selling shares of aTyr Pharma?: In the last twelve months, aTyr Pharma insiders bought shares 4 times. They purchased a total of 78,000 shares worth more than $136,160.00. The most recent insider tranaction occured on May, 31st when CFO Jill Marie Broadfoot bought 5,000 shares worth more than $8,950.00. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.
Information on this page was last updated on 5/31/2024.

Paul Schimmel Insider Trading History at aTyr Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2023	Buy	200,000	$2.25	$450,000.00	313,023
9/20/2021	Buy	250,000	$8.00	$2,000,000.00
5/18/2021	Buy	50,000	$3.98	$199,000.00	2,890
2/10/2020	Buy	254,000	$4.00	$1,016,000.00
11/26/2018	Buy	147,225	$0.54	$79,501.50
9/4/2018	Buy	42,749	$0.74	$31,634.26
8/30/2018	Buy	164,411	$0.74	$121,664.14
5/18/2018	Buy	150,000	$1.00	$150,000.00
8/31/2017	Buy	94,336	$2.65	$249,990.40	40,440
12/21/2016	Buy	25,000	$2.28	$57,000.00	40,440
12/16/2016	Buy	50,000	$2.48	$124,000.00	40,440
4/14/2016	Buy	66,219	$4.18	$276,795.42	53,012
4/13/2016	Buy	9,835	$3.85	$37,864.75	20,412
4/12/2016	Buy	9,127	$3.71	$33,861.17	20,412
4/11/2016	Buy	32,659	$3.57	$116,592.63	214,931
4/8/2016	Buy	85,000	$3.22	$273,700.00	187,572
4/7/2016	Buy	40,000	$3.19	$127,600.00	102,572
4/6/2016	Buy	25,000	$3.20	$80,000.00	62,572
4/5/2016	Buy	25,000	$3.52	$88,000.00	37,572

Paul Schimmel Buying and Selling Activity at aTyr Pharma

aTyr Pharma Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $1.76

$1.57

$2.07

2 Week Range

Now: N/A

Volume

269,400 shs

Average Volume

514,103 shs

Market Capitalization

$131.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Trump said you could learn something from this man

From Wide Moat Research | Ad

Here’s everything you need to know.